Advanced Neuroendocrine Carcinomas Of The Digestive System clinical trials

Explore recruiting advanced neuroendocrine carcinomas of the digestive system clinical trials.

Recruiting advanced neuroendocrine carcinomas of the digestive system studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Advanced Neuroendocrine Carcinomas Of The Digestive System trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase II Study Of Tarlatamab Alone Or In Combination With Chemotherapy In Advanced Neuroendocrine Carcinomas Of The Digestive System Or Unknown Primary Origin

Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Advanced Neuroendocrine Carcinomas Of The Digestive System trials by city

Advanced Neuroendocrine Carcinomas Of The Digestive System clinical trials

Recruiting advanced neuroendocrine carcinomas of the digestive system studies right now

Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies

A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

A Study of GV20-0251 in Advanced or Refractory Solid Tumors

Also recruiting in Europe

Phase II Study Of Tarlatamab Alone Or In Combination With Chemotherapy In Advanced Neuroendocrine Carcinomas Of The Digestive System Or Unknown Primary Origin

Advanced Neuroendocrine Carcinomas Of The Digestive System trials by city

Other conditions